<DOC>
	<DOC>NCT02924376</DOC>
	<brief_summary>The purpose of this study is evaluate the efficacy of INCB054828 in subjects with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 translocation who have failed at least 1 previous treatment.</brief_summary>
	<brief_title>Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy</brief_title>
	<detailed_description />
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<criteria>Histologically or cytologically confirmed cholangiocarcinoma. Radiographically measurable or evaluable disease per RECIST v1.1. Tumor assessment for FGF/FGFR gene alteration status completed through the central laboratory. Documented disease progression after at least 1 line of prior systemic therapy. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. Life expectancy â‰¥ 12 weeks. Prior receipt of a selective FGFR inhibitor. History of and/or current evidence of ectopic mineralization/calcification, including but not limited to soft tissue, kidneys, intestine, myocardia, or lung, excepting calcified lymph nodes and asymptomatic arterial or cartilage/tendon calcifications. Current evidence of corneal disorder/keratopathy, including but not limited to bullous/band keratopathy, corneal abrasion, inflammation/ulceration, keratoconjunctivitis, etc, confirmed by ophthalmologic examination. Use of any potent CYP3A4 inhibitors or inducers within 14 days or 5 halflives, whichever is shorter, before the first dose of study drug. Topical ketoconazole will be allowed.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Cholangiocarcinoma</keyword>
	<keyword>fibroblast growth factor (FGF)</keyword>
	<keyword>fibroblast growth factor receptor (FGFR)</keyword>
	<keyword>FGF/FGFR alterations</keyword>
</DOC>